

(To be published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
 Government of India
 Ministry of Chemicals and Fertilizers
 Department of Pharmaceuticals
 National Pharmaceutical Pricing Authority

New Delhi, 28th February, 2018

ORDER

S.O._____ In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/ revises the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)	Review Order number and date	Existing SO number and date
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1.	Furosemide	Injection 10mg/ml	1 ML	1.50	31015/19/2017- Pricing dated 24.08.2017	2058(E) dated 30.6.2017 (at Sl. No. 244)
2.	Snake Venom Antiserum-Soluble/ Liquid Polyvalent	Injection	Each Pack (10 ML)	392.64	31015/56/2017- Pricing dated 30.10.2017	2058(E) dated 30.6.2017 (at Sl. No. 539)
3.	Phenobarbitone	Oral liquid 20 mg/5 ml	1 ML	0.40	31015/37/2017- Pricing dated 28-09-2017	2058(E) dated 30.6.2017 (at Sl. No. 469)

Note:

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in

paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/187/55/2018/F

F. No. 8(55)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director

(To be published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, 28th February, 2018

Corrigendum

SO..... In the para 10 of Order No. S.O. 639(E) dated the 12th February, 2018 of the National Pharmaceutical Pricing Authority regarding fixation of ceiling prices of coronary stents, published in the Gazette of India, the word "05th January 2018" be read as "5th February 2018".

PN/187/55/2018/F

F. No. 8(55)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 28th February, 2018

ORDER

S. O. In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Atorvastatin + Aspirin Capsule (Atchol-ASP 150)	Each hard gelatin capsule contains: Atorvastatin Calcium eq. to Atorvastatin 10mg (as two film -coated tablets of 5 mg each) Aspirin 150mg (as two enteric coated tablets of 75mg each)	1 Capsule	M/s Aristo Pharmaceuticals Pvt. Ltd.	2.10
2.	Nifedipine + Lidocaine Cream (LOXHEAL)	Each 30mg cream contains: Nifedipine IP 0.3 percent w/w, Lidocaine IP 1.5 percent w/w, Imidurea IP (as Preservative) 0.2percent w/w in Cream base	1 GM	M/s Uttaranchal Biotech Ltd. / M/s Neon Laboratories Ltd.	3.14
3.	Pioglitazone + Gliclazide + Metformin Tablet (GLZ Total)	Each film coated tablet contains: Pioglitazone HCL IP eq. to Pioglitazone 15mg, Gliclazide IP 60mg (In modified release form) and Metformin HCL 500mg (extended release form)	1 Tablet	M/s M/s Mascot Health Seris Pvt. Ltd. / M/s Alembic Pharmaceuticals Limited	8.11
4.	Ibuprofen + Paracetamol Tablet (Brufen Plus)	Each film coated tablet contains: Ibuprofen IP 400mg Paracetamol IP 325mg	1 Tablet	M/s Innova Captab Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd.	1.04
5.	Misoprostol Tablet	Each uncoated tablet contains: Misoprostol IP 600mcg (As 1% Misoprostol dispersion)	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Bharat Serums and Vaccines Limited	56.81
6.	Glimepiride + Metformin Tablet	Each uncoated bilayered tablet contains: Glimepiride IP 3mg, Metformin Hydrochloride IP 850mg (in Sustained release form)	1 Tablet	M/s Windlas Biotech Ltd. / M/s Intas Pharmaceuticals Limited	7.05
7.	Melphalan + Povidone Injection (Melphalan Injection IP 50mg)	Each vial contains: Melphalan HCL IP eq. to Melphalan 50mg, Povidone IP 20mg and Diluent For Melphalan Injection 10ml	Each Pack	M/s Natco Pharma Ltd	1767.38

		each vial contains Sodium Citrate IP 0.2g Proylene Glycol IP 6ml Ethanol (96%) IP 0.52ml water for Injection			
8.	Trastuzumab Injection	Each Lyophilized vial contains: Trastuzumab 150mg Injection	1 Vial	M/s Cadila Healthcare Limited / M/s Emcure Pharmaceuticals Ltd.	18125.79
9.	Vitamin D3 (Cholecalciferol) (D-RISE SURE)	Each orally Disintegrating Strip contains: Vitamin D3 (Cholecalciferol) IP 60000 IU Orally Disintegrating Strip	1 Orally Disintegrating Strip	M/s Zim Laboratories Limited / M/s USV Limited	24.76

Note:

- (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/187/55/2018/F

F. No. 8(55)/2018/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director